

JOINT TRANSNATIONAL CALL FOR PROPOSALS (2022) FOR

“PREVENTION IN PERSONALISED MEDICINE”



PRELIMINARY ANNOUNCEMENT

ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 32 funding organisations have agreed to launch the fifth joint transnational call for collaborative innovative research projects in Personalised Medicine (PM). This represents the fourth call not co-funded by the European Commission. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.

The call is planned to be launched on **December 1st, 2021**, with a submission deadline for pre-proposals on **February 17, 2022**. It is expected, that consortia invited for the full-proposal stage, will need to submit their proposals **on June 14th, 2022**.

The available budget for this call is **27 Mio€ (approx.)**.

An open **information day introducing the joint transnational call 2022** to the research community will be organised by ERA PerMed on **December 9th, 2021**. More information will follow soon.

AIMS OF THE CALL

Through its fifth transnational call, ERA PerMed aims to foster research on prevention in personalised medicine. The overarching goal of the call is the development of tailor-made strategies for prevention of disease and disease progression, at three different levels:

- i. preventive measures decreasing the rate of incidence (primary prevention),
- ii. early detection to increase the efficacy of a preventive therapy, even before symptoms are developed (secondary prevention), and

- iii. interventions preventing disease recurrence or improving patients’ care and quality of life (tertiary prevention).

Research on prevention from over-treatment or overmedicalisation in primary, secondary and tertiary personalised preventive approaches is optional and could be part of research proposals, if applicable.

The clinical relevance of the proposed PM approach needs to be convincingly demonstrated.

The overall objectives of the ERA PerMed call are (i) to support **translational research projects** in the field of Personalised Medicine; (ii) to encourage and enable **interdisciplinary collaborations towards implementation of PM**, in combining pre-clinical or clinical research with bio-informatics components as well as ELSA research or implementation research, including health economics; (iii) to encourage **collaboration between academia** (research teams from universities, higher education institutions, public research institutions, research centres), **clinical/public health research** (research teams from hospital/ public health, healthcare settings and other healthcare organisations), private partners e.g. **SMEs** (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient organisations.

SCOPE OF THE CALL

The JTC2022 is constructed around the following three research areas in order to ensure the development of specific PM approaches considering the major aspects needed for their successful implementation in the health systems: (1) **“Translating Basic to Clinical Research and Beyond”**, (2) **“Data and Information and Communication Technology (ICT)”** and (3) **“Responsible and Effective Implementation in Healthcare”**.

Each proposal **MUST address at least one module out of each research area:**

Research area 1 “Translating Basic to Clinical Research and Beyond”	Research area 2 “Data and ICT”	Research area 3 “Responsible and Effective Implementation in Healthcare”
Module 1A: Pre-clinical Research	Module 2A: Enabling Technology	Module 3A: Health Economics and Implementation Support
Module 1B: Clinical Research	Module 2B: Towards Application in Healthcare	Module 3B: Ethical, Legal and Social Aspects

ICT: Information and Communications Technology (or Technologies)

Assessment of the coherent integration and combination of the different research areas and modules in the proposals is part of the evaluation process.

GENERAL (ELIGIBILITY) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

- A. Academia** (research teams working in universities, other higher education institutions) or **research institutes;**
- B. Clinical/public health sector** (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
- C. Private for-profit (industry) partners, e.g. SME** (small and medium-sized enterprises) and **private non-profit partners, e.g. foundations, associations or non-governmental organisations.**

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual ERA PerMed funding organisation respective of the region/country from which applicants have applied. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below "*Contact details of participating members*").

Only transnational projects will be funded. **Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate to the call** (see list below). All three legal entities must be independent from each other. At least **two partners** out of the minimum three eligible project partners of the consortium must be **from two different EU Member States or Associated Countries**.

The **maximum number of partners per pre-proposal is six** though not more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding). **At the full-proposal stage, a consortium might be increased up to seven partners in total only by inclusion of a partner coming from an underrepresented country**. A list of underrepresented countries will be provided to coordinators invited for full-proposals submission.

Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates

as such. **No more than one partner with own funding is allowed** in consortia with at least three partners eligible for funding.

The **project coordinator must be eligible to be funded** by his/her regional/national participating funding organisation.

It is mandatory to **integrate as principle investigator at least one early-career researcher in a consortium**.

Exception: To facilitate the integration of patient organisations in consortia, they can be added to a consortium as additional partners at the pre-proposal stage or the full-proposal stage. The consortia must follow all of the above-mentioned rules regarding consortia composition without counting the patient organisations. The latter can be added as additional partners either through their own funding or by applying for funding, if eligible, from the respective funding organisations. Not more than two consortium partners per country can request funding, including patient organisations. An exception is possible in countries with more than one funding organisation: in these countries, three partners from the same country may apply for funding, if one of them is a patient organisation and at least one of them is requesting funding to a regional funding organisation.

Number of partners in the proposal*	Pre-proposal				Full-proposal (only by inclusion of one underrepresented country)
	3	4	5	6	7
Maximum number of partners with own funding**	0	1	1	1	1
Maximum number of partners per country***	1	2	2	2	2

* minimum 3 partners eligible for funding from three different countries participating in the call. Patient organisations are not counted in this calculation.

** patient organisations are not counted in this calculation and can be added as partners participating with own funding in the pre- and full-proposal step.

*** patient organisations are not counted in this calculation and can be added as additional partners in the pre-proposal or full-proposal stage. They can participate either on own funds or apply for funding, if eligible, from the regional/national funding organisation. Please note: **Not more than two consortium partners per country can request funding, including patient organisations.** For some funding agencies, the maximum number of eligible partners that can be funded in one project is limited to one. In countries with more than one funding organisation, three partners from the same country may apply for funding, if one of them is a patient organisation and at least one of them is requesting funding to a regional funding organisation.

ICPERMED PARTNERING TOOL

If you are looking for potential partners, please have a look also at the **ICPerMed Partnering Tool**: <https://partnering.pt-dlr.de/ICPerMed>

The ICPeMed Partnering Tool facilitates networking among universities, clinical sector, research and patient organisations, SMEs, industry and all other stakeholders interested in personalised medicine. The tool enables users to present their expertise to the personalised medicine research community and to search for partners. By completing and activating the profile, it becomes available to all users. The partner search function is available for all users, also for those who do not publish their partnering profile. The tool assists users in finding suitable cooperation partners. The tool might be of particular help for applicants coming from countries that joined ERA PerMed calls recently.

PARTICIPATING MEMBERS, ASSOCIATED COUNTRIES AND REGIONS

The following countries (25) are participating in the preparation of the call: Austria*, Belgium, Brazil*, Canada, Chile, Croatia, Denmark, Estonia, France, Germany, Hungary*, Ireland*, Israel, Italy, Latvia, Luxembourg, Norway, Poland, Romania*, Slovenia, South Africa, Spain, Sweden, Taiwan and Turkey (contact list is provided in Annex 1).

Besides national funders, the following regions are participating (7): Wallonia-Brussels (Belgium), Quebec (Canada), Federation Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain) and one Charity (AECC-FC).

*decision on participation is still pending

Please Note:

The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication.

Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.

The final call information is expected to be published on the ERA PerMed website by **December 1st, 2021.**

ANNEX 1: CONTACT DETAILS OF PARTICIPATING MEMBERS

Country	Funding Organisation	Contact point	Email
AUSTRIA	FWF*	Milojka Gindl Ena Linnau	milojka.gindl@fwf.ac.at ena.linnau@fwf.ac.at
BELGIUM (WALLONIA- BRUSSELS FEDERATION)	F.R.S.-FNRS	Joël Groeneveld Florence Quist	international@frs-fnrs.be
BRAZIL	CONFAP*	Elisa Natola	elisa.confap@gmail.com
CANADA (QUEBEC)	FRQS	Maxime Beaudoin	Maxime.beaudoin@frq.gouv.qc.ca
CHILE	ANID	Andrea Cibotti Ortiz	acibotti@anid.cl
CROATIA	MSE	Mateo A. Bosnić	MateoAnte.Bosnic@mzo.hr
DENMARK	InnoFond	Ejner Moltzen	Ejner.moltzen@innofond.dk
ESTONIA	ETAg	Margit Suuroja	margit.suuroja@gmail.com
FRANCE	ANR	Monika Frenzel Michael Joulie	ERAPerMed@agencerecherche.fr
GERMANY	BMBF/DLR	Katja Kuhlmann Alexandra Becker	permed@dlr.de
GERMANY	BMG/DLR	Katja Kuhlmann Alexandra Becker	permed@dlr.de
GERMANY (SAXONY)	SMWK	Eva-Maria Stegemann Gabriele Süptitz	permed@smwk.sachsen.de
HUNGARY	NKFIH*	Klára Horváth	klara.horvath@nkfi.gov.hu
IRELAND	HRB*	TBD	TBD
ISRAEL	CSO-MOH	Yahaloma Gat Liron Even-Faitelson	y.gat@moh.gov.il liron.ef@moh.gov.il
ITALY	IT-MOH	Maria Josè Ruiz Alvarez Chiara Ciccarelli	mj.ruizalvarez-esterno@sanita.it c.ciccarelli@sanita.it
ITALY (LOMBARDY)	FRRB	Paola Bello, Giusi Caldieri, Marcello De Amico, Carmen De Francesco	bandi@frrb.it
ITALY (TUSCANY)	TUSCREG	Donatella Tanini Teresa Vieri	erapermed@regione.toscana.it
LATVIA	VIAA/LCS	Maija Bundule Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
LUXEMBOURG	FNR	Marie-Claude Marx	marie-claude.marx@fnr.lu
NORWAY	RCN	Karianne Solaas	kso@rcn.no
POLAND	NCBR	Marcin Chmielewski	marcin.chmielewski@ncbr.gov.pl
ROMANIA	UEFISCDI*	Cristina Laura COTET	cristina.cotet@uefiscdi.ro
SLOVENIA	MIZS	Eva Batista	eva.batista@gov.si

SOUTH AFRICA	SAMRC	Rizwana Mia	Rizwana.Mia@mrc.ac.za
SPAIN	ISCIII	Jowita Magdalena Spytowska Cristina Nieto García Mauricio García-Franco	eranetpm@isciii.es
SPAIN	FCAECC	Esther Aguilar Marta Puyol	esther.aguilar@contraelcancer.es marta.puyol@contraelcancer.es
SPAIN (CATALONIA)	DS-CAT	Montserrat Llavayol	peris@gencat.cat
SPAIN (NAVARRRE)	GN	Sara Torres	storresl@navarra.es
SWEDEN	VINNOVA	Malin Eklund	malin.eklund@vinnova.se
TAIWAN	MOST	Ching-Mei Tang	cmtom@most.gov.tw
TURKEY	TUBITAK	Emine Derebay Yildiz	emine.derebay@tubitak.gov.tr

*decision on participation is still pending